 |
There aren’t many drugs currently in late development for rosacea. Finacea foam and Soolantra have been approved, and it looks like Azultro is on the way. One of the remaining drugs that is still inching its way through the approval process is Omiganan.
Confirmation that Omiganan is still alive in the rosacea development pipeline comes from a recent article from Medscape Dermatology. It has been a long time in development, first coming to our attention in 2006. So perhaps there indeed is another drug on the horizon for the papules and pustules of rosacea.
The Rosacea Pipeline
Omiganan is a cationic antimicrobial peptide, a first-in-class for rosacea, that is entering into phase 3 trials. In a phase 2 dose-ranging study (N=240),[18] it showed a dose-dependent reduction in inflammatory lesions. The 2.5% formulation resulted in a 40% reduction at week 9. Cutaneous tolerability was good.
